Renaud Bonnet is co-leader of Private Equity for the Firm's Corporate Practice. His practice areas include venture capital, private equity, M&A, and capital markets. He represents technology and life sciences companies, as well as the private equity and industrial investors that finance them, at every stage of development from entrepreneurial start-ups to multibillion dollar global corporations. He has acted as principal lawyer in a significant number of early to late-stage financing rounds, LBO and other M&A transactions, joint ventures, initial public offerings, rights issues, private placements, and tender offers.
Renaud's recent experience includes representations of technology and life sciences companies Adocia, Ansys, Cellectis, Criteo, Deezer, Devialet, EcoVadis, HRA Pharma, Ivalua, 360Learning, ManoMano, Nanobiotix, Planisware, Prodways, Sigfox, Talend, and Voltalia. His recent investor-side representations include: Abingworth, Alven, Bain Capital Ventures, Bpifrance, Creadev, Danone Ventures, Elaia, Felix Capital, Goldman Sachs, Orange, Hi Inov, Idinvest, Institut Pasteur, Sanofi, Seventure, Sofinnova, and Temasek.
Transactions in which Renaud acted as lead lawyer include: representing the issuer and/or underwriters in more than 100 IPOs and follow-on offerings; the IPOs of Criteo, Cellectis, Nanobiotix, and Talend on Nasdaq; the tender offers on Completel, Wavecom, Assystem, and TxCell; the LBOs of HRA Pharma by Astorg and Goldman Sachs, Orolia by Eurazeo, A2Mac1 by Five Arrows, and Brico Privé by Florac; the sale of Novexel to AstraZeneca and Synthesio to Ipsos; the acquisition of French technology companies by Autodesk, Criteo, SAP, and Ansys; and the latest financing rounds of Devialet, Ivalua, ManoMano, and EcoVadis.
Renaud was a member of the Consultative Commission on Issuers' Transactions and Financial Information of the French Financial Markets Authority (AMF) from 2017 to 2019.
- 29 janvier 2014
Le private equity en 2014 : tendances et opportunités
- 29 janvier 2013
Le Private Equity : où en sommes-nous ?
- 20 septembre 2012
Le financement des PME: actualités juridiques et tendances de marché - en partenariat avec NYSE Euronext et Société Générale
- September 20, 2012
SME Financing: legal news and market trends – in collaboration with NYSE Euronext and Société Générale
- 5 avril 2011
Atelier « Fusions & Acquisitions » de France Biotech - Le point de vue de l'avocat, intervention de Renaud Bonnet
- 17 juin 2009
Introductions en bourse : la mission de l’avocat conseil et la problématique règlementaire, Conférence “Penser à votre introduction en bourse : osé ... mais peut-être astucieux ! ” organisée par la Société Générale
- 3 avril 2007
Introductions en bourse : feuille de route pratique
- 18 mai 2006
Petit déjeuner thématique "Stock options, BCE, actions gratuites"
- 14 mars 2006
Cours à l'ESSEC, "Mécanisme d'incitation des managers"
- Columbia University (LL.M. 1997; Harlan Fiske Stone Scholar); Université de Paris II-Panthéon Assas (DESS/DJCE in Business Law and Taxation 1994; Double Maîtrise with honors and high honors 1993); ESSEC Graduate School of Management (MBA 1993); Institut d'Etudes Politiques de Paris (Sciences Po) (Diplôme — section Service Public 1991)
- Paris and New York Bars
Ranked annually as a leading lawyer for private equity/venture capital, equity capital markets, M&A, and life sciences (Chambers Europe, The Legal 500, Private Equity Magazine, Leaders League)
"Best Lawyer in France" for venture capital, Best Lawyers/Les Echos (2018)
"Private Equity Lawyer of the Year," Option Droit & Affaires (2018)
First prize for number of capital markets transactions, Le Magazine des Affaires (2017)
- English, French
*Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice